688366 Shanghai Haohai Biological Technology
- 92.96
- +0.46+0.50%
Shanghai Haohai Biological Technology News
May 13 Repurchase Collection | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$217 million
According to HKEx disclosure documents on May 14, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.1976 million common shares on May 10, involving an amount of HK$217 million. The repurchase price per share ranged from HK$68.15 to HK$67.8. ② $Hang Seng Bank (00011.HK) $ repurchased 300,000 common shares on May 13, involving an amount of HK$32.698,700. The repurchase price per share ranged from HK$109.4 to HK$10
On May 13, Haohai Biotechnology (06826) spent about 12.372 million yuan to buy back about 133,400 A shares
According to the Zhitong Finance App, Haohai Biotechnology (06826) announced that on May 13, 2024, it spent about 12.372 million yuan to buy back about 133,400 A-shares.
Haohai Biotech (688366): The first quarter's performance grew rapidly, and the R&D pipeline continued to advance steadily
Incident: On April 29, the company released its report for the first quarter of 2024. In the first quarter, it achieved operating income of 646 million yuan, an increase of 5.68% over the previous year, and achieved net profit of 975.415 million yuan, an increase of 20 percent over the previous year.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Haohai Biotech (688366): The performance is in line with expectations, and the medical, aesthetic and ophthalmology businesses are working together
Core view In 2023, the company's revenue, net profit to mother, and net profit after deducting non-return to mother increased by 24.59%, 130.58%, and 141.52% year-on-year respectively. The overall performance growth was in line with expectations. Ophthalmic lenses and medical and aesthetic hyaluronic acid were in line with expectations.
Haohai Biotechnology (06826.HK) did not implement share repurchases in April
Gelonghui, May 6, 丨 Haohai Biotechnology (06826.HK) announced that in April 2024, the company did not implement a share repurchase. As of April 30, 2024, the company has repurchased a total of 1,346,828 A-shares through centralized bidding transactions, accounting for 0.80% of the company's total share capital of 168,707,203 shares. The highest transaction price was 113.50 yuan/share, the minimum transaction price was 84.26 yuan/share, and the total transaction amount was RMB 140,085,716.25 (excluding transaction fees such as stamp duty and transaction commissions).
The market is picking up, and listed companies are pouring in medical and aesthetic institutions. Who will win the next “C-rank material”?
Catalyzed by various factors, the medical and aesthetic market recovered to a certain extent in the first quarter, while the performance of listed companies, whether midstream medical and aesthetic institutions or upstream producers, has steadily improved since this year.
Haohai Biotechnology (06826.HK): The Q1 profit side slightly exceeded expectations and the profitability was significantly optimized
Incident: [Haotahaibl Student _ Wusu Science MM Technology A Release] Published the 2024 Quarterly Report, Q1 achieved revenue of 646 million yuan/ +5.68%, and net profit of 98 million yuan/ +20.16%
Haohai Biotech (688366): Net profit after deducting non-return to mother increased 33%, expecting fourth-generation hyaluronic acid to be approved
Incident: The company released its 2024 quarterly report: 24q1 achieved revenue of 646 million yuan/yoY +5.68%, achieved net profit of 97.54 million yuan/yoy +20.16%, and achieved net profit deducted from non-mother 95
昊海生物科技：2024年第一季度報告
[Stock Exchange Amendment] Jiang Wei sold 1.73 million A-shares of Haohai Biotechnology (06826.HK), worth about 156 million yuan
On April 29, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 29, on July 3, 2023, Jiang Wei sold $1.73 million A-shares of $Haohai Biotechnology (06826.HK) at an average price of 90.0 yuan (RMB, same unit), worth about 156 million yuan. After the sale, Jiang Wei's latest shareholding was 77.99 million shares, and the good position ratio dropped from 57.60% to 56.35%. Additional information: The 1,730,000 A-share shares of the listed corporation sold by Mr. Jiang Wei on July 3, 2023 are through the Shanghai Zhanze enterprise management partnership under his control
HAOHAI BIOTEC To Go Ex-Dividend On June 6th, 2024 With 1.10175 HKD Dividend Per Share And 0.4 Stock Dividend Per Share
April 27th - $HAOHAI BIOTEC(06826.HK)$ is trading ex-dividend on June 6th, 2024. Shareholders of record on June 7th, 2024 will receive 1.10175 HKD dividend per share and 0.4 stock dividend per sha
Haohai Biotechnology (06826) will pay a final dividend of 1 yuan per share on July 19
Haohai Biotechnology (06826) issued an announcement that it will be distributed on July 19, 2024 until 2024 until 2023...
Haohai Biotechnology (06826.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Haohai Biotechnology (06826.HK) issued an announcement. The board of directors hereby announces that a board meeting will be held on April 29, 2024 (Monday) to review and approve (including) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
Haohai Biotech (688366) First Coverage Report: Biomaterials Industry Leaders Build a Comprehensive Platform for Medical Devices+Medical and Aesthetic Consumption
The company is a leader in the biomaterials segment, opening up a development ceiling for incremental ophthalmology and medical and aesthetic business layouts. Established in 2007, Haohai Biotech is mainly engaged in R&D, production and sales of medical device products. The company uses a “self-development+acquisition” policy
昊海生物科技：董事會會議召開日期
Minsheng Securities released a research report on April 17 stating that it gave Haohai Biotech (688366.SH) a recommended rating. The main reasons for the rating include: 1) the company is a leader in the biomaterials segment, opening the development ceili
Minsheng Securities released a research report on April 17 stating that it gave Haohai Biotech (688366.SH) a recommended rating. The main reasons for the rating include: 1) the company is a leader in the biomaterials segment, opening the development ceiling for the incremental ophthalmology and medical aesthetic business layout; 2) the ophthalmology and medical aesthetic market continues to grow rapidly, driven by internal and external factors, and iterations of innovative products drive the sustainability of the industry's growth; 3) the company has a comprehensive business layout and strong competitiveness in the ophthalmology and aesthetic business. (Mainichi Keizai Shimbun)
HAOHAI BIOTEC: ANNUAL REPORT 2023
Tianfeng Securities released a research report on April 11 stating that it gave Haohai Biotech (688366.SH) a purchase rating. The main reasons for the rating include: 1) sales of hyaluronic acid products are growing rapidly, and the company's revenue grow
Tianfeng Securities released a research report on April 11 stating that it gave Haohai Biotech (688366.SH) a purchase rating. The main reasons for the rating include: 1) sales of hyaluronic acid products are growing rapidly, and the company's revenue growth is in line with expectations; 2) third-generation hyaluronic acid drives gross margin growth, and the fourth generation has already entered the post-filing stage; 3) the acquisition of all shares of Euroamerica, and the development of ophthalmic products is progressing in an orderly manner. (Mainichi Keizai Shimbun)
Haohai Biotech (688366): High-end hyaluronic acid is growing rapidly, and development of ophthalmic products is progressing in an orderly manner
Event: The company released its 2023 annual report. In 2023, it achieved operating income of 2,654 billion yuan, an increase of 24.59% over the previous year; achieved net profit of 416 million yuan, an increase of 130.58% over the previous year; achieved after deduction
Analysis
Price Target
No Data
